Mustang Bio Gets FDA Acceptance of IND Application for MB-109 Cancer Treatment
By Chris Wack
Mustang Bio said that the U.S. Food and Drug Administration has accepted its Investigational New Drug application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.
The biopharmaceutical company is planning to initiate a Phase 1 multicenter clinical trial at the University of Alabama at Birmingham to assess the safety, tolerability and efficacy of MB-109 in adult patients with recurrent GBM and high-grade astrocytomas.
Mustang said that FDA acceptance of the IND within 30 days of initial submission was positive for the potential treatment.
The Phase 1 study is expected to begin enrolling patients in 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 26, 2023 09:34 ET (13:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track